12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brilinta regulatory update

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment for cardiovascular drug Brilique ticagrelor from AstraZeneca. G-BA said Brilique provides an "important additional benefit" compared with clopidogrel and aspirin in patients with non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable angina, which is in line with an October preliminary...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >